Description

16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED listed on BSE effective January 1, 2026, issued through preferential allotment via warrant conversion.

Summary

BSE has listed 16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED (Scrip Code: 536565) effective from January 1, 2026. These shares were issued at Rs. 20/- per share (face value Rs. 10/- with a premium of Rs. 10/-) to Promoter and Non-Promoter entities on a preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.

Key Points

  • Total new shares listed: 16,61,000 equity shares of Rs. 10/- each
  • Issue price: Rs. 20/- per share (including premium of Rs. 10/-)
  • Allotment date: October 23, 2025
  • Trading commencement: January 1, 2026
  • Distribution numbers: 14480001 to 16141000
  • ISIN: INE314I01036
  • Basis: Preferential allotment through warrant conversion
  • Rank: Pari-passu with existing equity shares

Regulatory Changes

No regulatory changes announced. This is a routine listing notification.

Compliance Requirements

Trading members must note the following lock-in restrictions:

  • 11,25,000 shares (Dist. Nos. 14480001 to 15605000): Locked-in until July 31, 2027
  • 5,36,000 shares (Dist. Nos. 15605001 to 16141000): Locked-in until July 31, 2026

Important Dates

  • Allotment Date: October 23, 2025
  • Trading Start Date: January 1, 2026
  • Lock-in Expiry (Partial): July 31, 2026 (5,36,000 shares)
  • Lock-in Expiry (Full): July 31, 2027 (11,25,000 shares)

Impact Assessment

This listing has minimal market-wide impact as it pertains to a single company’s preferential allotment. The lock-in periods ensure that the majority of shares (11,25,000) cannot be traded until July 2027, limiting immediate liquidity impact. Investors in NOVELIX PHARMACEUTICALS LIMITED should note the increased share capital and dilution effect of approximately 16.61 lakh new shares entering the market.

Impact Justification

Routine listing of preferentially allotted shares for a single company with limited market-wide impact.